

Form PTO-1449 (Modified)	ATTY. DOCKET NO. <b>346B USC1</b>	SERIAL NO. <b>10/002,224</b>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT: <b>Gilman</b>	
<b>STATEMENT</b>	FILING DATE: <b>10/23/01</b>	GROUP <b>1632</b>

**OIP**  
JAN 29 2002  
PATENT & TRADEMARK OFFICE

### OTHER ART

(Including Author, Date, Publication, Title, Pertinent Pages)

RLS		Hollenberg and Evans, (1988) Cell, 55: 889-906.
	10	Tate et al., (1996) FASEB J., 10: 1524-1531.
	11	Sauer, (1995) Science 270: 1783-1788.
	12	Sublett et al., (1995) Oncogene, Aug 3; 11(3): 545-52.
	13	Le Douarin et al., (1995) Nucleic Acids Research, 23: 876-878.
	14	Oligino et al., (1996) Gene Therapy, 8: 892-899.
	15	Veelken et al., (1998) Int J Mol. Med., 2(4): 423-428.
	16	Liu et al., (1993) Immunology Today, 14:290-295, 1993.
	17	Orkin et al., (1995) Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy
	18	Orloff et al., (1990) Nature 347:189-190.
	19	Qi et al., (1995) Mol Cell Biol., 5:1817-1825.
	20	Sadowski et al., (1993) Nature 362:79-83.
	21	Weintraub et al., (1991) Science 251:761-766.
	22	Fishman et al., (1994) J. Clin. Invest. 93:1864-1868.
	23	Bergmann et al., (1994) J. Steroid Biochem. Molec. Biol., 49:139-152.
	24	Li and Brasler, (1996) Molecular Endocrinology 10:252-264.
	25	Baim et al., (1991) Proc Natl Acad Sci USA 88:5072-5076.
	26	Pruschy et al., (1994) Chemistry & Biology, 1(3): 163-171.
	27	Becker et al., (1989) Mol. Cell. Biol., 9(9): 3878-3887.
	28	Chapman et al., (1996) Mol. Endocrinol., 10: 967-978.
	29	Schmitz and Baeuerle (1991) EMBO J. 10:3805-3817.
	30	Selden et al., (1987) Science 236:714-718.
	31	Burcin et al., (1999) Proc Natl Acad Sci USA 96:355-360.
	32	Rivera et al., (1996) Nature Medicine 2:1028-1032.
	33	Rivera et al., (1999) Proc Natl Acad Sci USA 96:8657-8662.
RLS	34	Ye et al., (1999) Science 283:88-91.

RLS


12/31/03

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.

Form PTO-1449 (Modified)	ATTY. DOCKET NO. 346B USC1	SERIAL NO. 10/002,224
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Gilman	
	FILING DATE: 10/23/01	GROUP 1632



### U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
RLS		5,830,462	11/3/98	Crabtree et al.	424	93.21	6/7/95
		5,654,168	08/05/97	Bujard et al.	435	69.1	
		5,082,670	1/21/92	Gage et al.	434		
		5,262,300	11/16/93	Evans et al.	435	6	
		5,534,418	7/9/96	Evans et al.	435	69.1	
RLS		5,597,693	1/28/97	Evans et al.	435	6	

### FOREIGN PATENT DOCUMENTS

Exam Init	Ref Des	Country & Doc. No. (11)	Pub. Date (43)	Name	Class	Sub Class	Translation Yes	No
RLS		WO 97/12040	4/3/97	Anrather et al.				
RLS		WO 96/41865	12/27/96	Clackson et al.				

### OTHER ART

(Including Author, Date, Publication, Title, Pertinent Pages)

RLS		1	Ruben et al., (1992) Mol Cell Biol 12:444-454.
		2	Blair et al., (1994) Mol Cell Biol 14:7226-7234.
		3	Emami and Carey (1992) EMBO J. 11:5005-5012.
		4	Kodadek and Johnston (1995) Chemistry and Biology 2:187-194.
		5	Paal (1997) Nucleic Acids Research, 25(5): 1050-1055.
		6	Lin et al., (1988) Cell, 54: 659-664.
		7	Schmitz et al., (1995) J. Biol. Chem., 270: 15576-15584.
RLS		8	White et al., (1992) EMBO J. Jun;11(6):2229-40.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.